Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XNCR vs IMVT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMVT Captures Overall Composite Edge (39.6 SELL vs 29.6 SELL), While XNCR Leads 4–2 on Growth & Valuation Pillars

IMVT Overall Winner 6-Pillar Tally: XNCR 4 – 2 IMVT Matrix Metrics: XNCR 5 – 5 IMVT

As of Nov 16, 2026, Immunovant, Inc. (IMVT) captures the overall head-to-head institutional edge over Xencor, Inc. (XNCR) on higher Unified Composite conviction (39.6/100 SELL vs. 29.6/100 SELL) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while XNCR wins 4–2 across the 6-pillar growth and valuation breakdown. XNCR trades at $35.61 (68.0x Forward P/E, -72.7% operating margin) versus IMVT at $33.30 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: IMVT earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. XNCR 29.6/100 SELL) and 1.74β · 72% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both XNCR (29.6/100 SELL) and IMVT (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs IMVT
XNCR NASDAQ
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52
IMVT NASDAQ Head-to-Head Winner
Immunovant, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$33.30
-2.56% 1D
Market Cap $7.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 72% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 36.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $30.82 · SMA50: $32.52

6-Pillar Scorecard Institutional Category Breakdown (XNCR 4 – 2 IMVT)

Columns: Metric · XNCR · IMVT
1. Valuation Multiples XNCR
Forward P/E 68.0x N/M
Trailing P/E 68.0x N/M
PEG Ratio N/M N/M
EV / Revenue 14.8x N/M
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $200M N/A
Market Cap $2.9B $7.3B
3. Profitability & Quality IMVT
Gross Margin -42.5% N/A
Operating Margin -72.7% 0.0%
Net Profit Margin -58.8% 0.0%
Return on Equity (ROE) -19.9% -86.5%
4. Balance Sheet & Cash Flow XNCR
Cash Generation (TTM) -$176M -$395M
Cash Flow Margin -88.0% N/A
Net Cash / Leverage $101M Net Debt (0.29x D/E) $3.18 Book/Sh · -86.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMVT
Options Structure Phase BREAKOUT CONSOLIDATION
Current IV / %ile 79.0% (10th %ile) 54.1% (6th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity 30.2% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (5) vs IMVT (5)
Institutional Metric XNCR IMVT Criterion Row Edge
Market Capitalization
Scale
$2.9B $7.3B Larger Scale IMVT
Trailing P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Forward P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Revenue Growth (YoY)
Growth
+454.9% +0.0% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% 0.0% Higher Margin IMVT
Net Profit Margin
Profitability
-58.8% 0.0% Higher Margin IMVT
Return on Equity (ROE)
Capital Efficiency
-19.9% -86.5% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($10–$41) 49% ($22–$45) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.21β · 87% Vol 1.74β · 72% Vol Lower Realized Risk IMVT
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 39.6 / 100 (SELL) Higher Composite IMVT
Trailing 12M Revenue (USD)
Operating Scale
$200M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$395M ($3.18 Book/Sh · -86.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +31.24 pp
XNCR: +55.84% · IMVT: +24.6%
3M Horizon XNCR +64.96 pp
XNCR: +40.14% · IMVT: -24.82%
6M Horizon XNCR +196.43 pp
XNCR: +221.97% · IMVT: +25.54%
1Y Horizon XNCR +108.59 pp
XNCR: +154.54% · IMVT: +45.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XNCR vs IMVT. Trailing 12-month operating profitability (XNCR -72.7% vs IMVT 0.0%) and valuation multiples (XNCR 68.0x vs IMVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XNCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$200M
Gross Margin-42.5%
Op. Margin-72.7%
ROE / Fwd P/E-19.9% · 68.0x
IMVT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-86.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMVT CONSOLIDATION
93d in phase · OBV ACCUMULATION
Current IV 54.1%
IV Percentile 6th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
IMVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs IMVT Key Questions & Quantitative Answers

As of Nov 16, 2026, Immunovant, Inc. (IMVT) captures the overall head-to-head institutional edge over Xencor, Inc. (XNCR) on higher Unified Composite conviction (39.6/100 SELL vs. 29.6/100 SELL) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while XNCR wins 4–2 across the 6-pillar growth and valuation breakdown. XNCR trades at $35.61 (68.0x Forward P/E, -72.7% operating margin) versus IMVT at $33.30 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IMVT earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. XNCR 29.6/100 SELL) and 1.74β · 72% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both XNCR (29.6/100 SELL) and IMVT (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with IMVT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XNCR generates $200M in USD-normalized revenue versus N/A for IMVT. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMVT.

XNCR screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas IMVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus IMVT (-86.5% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, IMVT carries 54.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.